The bromodomain inhibitor JQ1 suppresses c-MYC signaling, among its many other effects in PCa, yet our findings indicate that high XBP1s tumors may be more resistant to JQ1 (Supplementary Fig. 9d), due to the potentially higher c-MYC levels. Here, MYC is linked to posterior cortical atrophy.